⌕
Spyre Therapeutics · SYRE · Nasdaq
Tenet 43 · Weak
Compare
$93.81−5.60%At closeTenet 43 · Weak
$93.81−5.56 (−5.60%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Spyre Therapeutics (SYRE) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

27 figures withheld by our checks. Each blank figure names its reason.

Estimates are in the company's reporting currency and are not compared to the USD share price on this page. Filed figures are in US dollars. Nothing here converts between the two.
Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Spyre Therapeutics to lose 3.12 a share in FY26 and 5.01 in FY30. 10 analysts publish an estimate for FY26 and 4 for FY30.

Forward P/E · FY26E
Not shown
the estimate and the price are in different currencies
FY26 EPS revisions · 31 days
▼ −14.5%
−2.72 to −3.12, one fiscal year at both ends
Disagreement · FY26
0.59
wide, −3.43 to −2.84
Coverage · FY26
10 · 7
EPS estimates · revenue estimates
Work out what the consensus implies at a multiple you chooseConsensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Are estimates going up or down lately?

The FY26 EPS consensus is −3.12, a loss that widened 15.0% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−18.9%−7.7%+3.6%FY27 −14.7%FY26 −15.0%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 6
FY2610 analysts▼ −14.5%−2.72 to −3.12▼ −15.0%−2.71 to −3.12▼ −3.5%−3.01 to −3.12
FY2711 analysts▼ −6.1%−3.60 to −3.81▼ −14.7%−3.33 to −3.81▼ −18.9%−3.21 to −3.81
Dec '269 analysts▼ −27.2%−0.80 to −1.01▼ −37.1%−0.74 to −1.01▼ −37.1%−0.74 to −1.01
Mar '273 analysts23 of 30 days−19.2% so far23 of 90 days−19.2% so far▼ −19.2%−0.81 to −0.97

Contributors at both ends of the window: FY26 10 and 10. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

The near-year consensus is −3.12 a share in the company's reporting currency, and a ratio carries no currency, so a multiple can still be chosen. We stop before the product: it would be a price in the reporting currency, and this share trades in US dollars.

Consensus EBITDA · FY26
−0.2B
10 analysts · low −0.2B, high −0.2B · thin coverage
Multiple · EV/EBITDA · yours
No year of positive EBITDA or earnings on record to take a default from, so the multiple can only be yours.
Receipt · SYRE · FY26Nov 16, 2026
Implied, a share
Not computed

We do not convert currencies here. The estimate is in the reporting currency and the share trades in US dollars, so the product would be a price in neither.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Not computed across currencies. The consensus is in Spyre Therapeutics' reporting currency and the share trades in US dollars, so there is no multiple of this year's estimate to set against a growth rate.

How much do analysts disagree?

For FY30, estimates run from −5.01 to −5.01 around an average of −5.01, drawn by 4 analysts.

FY26E10 analysts
−3.43 to −2.84 · 0.59 wide
FY27E11 analysts
−4.59 to −3.41 · 1.18 wide
FY28E11 analysts
−5.31 to −3.51 · 1.80 wide
FY29E4 analysts
−5.04 · only 4 estimates
FY30E4 analysts
−5.01 · only 4 estimates

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. The last filed figure is in US dollars, so it is not placed on this axis. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Spyre Therapeutics to lose 1.01 a share in the December quarter, the average of 9 estimates. Results are expected by Feb 19, 2027.

Expected report
Feb 19, 2027
Expected by Feb 19. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
0.0K
0 analysts, 0.0 to 0.0 in reporting ccy K

For the March quarter, analysts expect a loss of 0.97 a share.

Does Spyre Therapeutics usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Spyre Therapeutics begins on Jul 6, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported. The next report is expected by Feb 19, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Before our record
Mar '24
Sep '24
Jun '25
Our record, one quarter per report
Dec '23left out · currency
Jun '24left out · currency
Dec '24left out · currency
Mar '25left out · currency
Sep '25left out · currency
Dec '25left out · currency
Mar '26left out · currency
Jun '26left out · currency
Sep '26left out · currency
reportsFeb 19
Dec '26
Mar '27
Jun '27
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Spyre Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 88.1% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

10 analysts publish an EPS estimate for FY26 and 7 publish revenue. Coverage thins with distance: 4 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
710
FY26E
1011
FY27E
811
FY28E
64
FY29E
64
FY30E
The FY26 panel has held 10 analysts every night since our record of it began on Jul 6, 2026.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · reporting ccy Bfiled · consensus average · band = low to high
−0.00.10.2historyStreet forecastFY22FY23FY30E

Coverage thins with distance: 7 revenue estimates for FY26, 6 for FY30.

Diluted EPS · reporting ccyfiled · consensus average · band = low to high
Not enough estimate history to chart yet.

Out-year bands widen as fewer analysts publish: 10 EPS estimates for FY26, 4 for FY30.

Fiscal yearRevenue reporting ccy BYoYEPS reporting ccyYoYEBITDA reporting ccy BNet inc. reporting ccy BShares BAnalysts rev · EPSFwd P/E
FY25Filed · USD———————as filed—
FY26E0.00.0 to 0.0n/ca−3.12−3.43 to −2.84n/ca−0.2−0.20.067 · 10—
FY27E0.00.0 to 0.0▲88.1%−3.81−4.59 to −3.41—−0.2−0.30.0710 · 11—
FY28E0.00.0 to 0.0▲20.0%−4.48−5.31 to −3.51—−0.3−0.30.068 · 11—
FY29E0.10.1 to 0.1▲28563.0%−5.04−5.04 to −5.04n/cb−0.3−0.30.066 · 4—
FY30E0.20.2 to 0.2▲165.9%−5.01−5.01 to −5.01—−0.3−0.30.066 · 4—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 10 EPS estimates for FY26, 7 for revenue. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.